Literature DB >> 3958769

Improved methods for venous access: the Port-A-Cath, a totally implanted catheter system.

S Strum, J McDermed, A Korn, C Joseph.   

Abstract

We prospectively evaluated the performance and rate of long-term complications with the Port-A-Cath (PAC), a totally implanted vascular access system. Two catheter styles were evaluated, a small-bore (SB) catheter (0.51-mm diameter) and a large-bore (LB) catheter (1.02-mm diameter), in conjunction with the use of a strict catheter care protocol. The PAC performed well, and with both SB and LB systems, no significant extravasation, skin necrosis, hematoma, septum damage or leakage, or subcutaneous portal infections occurred after 7,240 days of implantation and 1,435 days of use. Complications with the PAC system consisted of catheter occlusion (seven patients, 21.5%) and one instance of possible catheter infection (3.1%). Occlusions were limited to patients implanted with the SB catheter (seven of 16, 43.8%), and five of the seven (71.4%) occurred in patients receiving continuous infusion chemotherapy and/or total parenteral nutrition. Patency of the PAC system was maintained using a regular flushing schedule once every 30 days, a significant advantage compared with the daily maintenance schedule required with externally placed venous catheters. The results of this study suggest that the PAC system can provide a safe and reliable method for venous access in patients requiring intermittent or prolonged intravenous therapy.

Entities:  

Mesh:

Year:  1986        PMID: 3958769     DOI: 10.1200/JCO.1986.4.4.596

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  11 in total

1.  Persistent left superior vena cava: a reason for pseudodisplacement of a port catheter.

Authors:  L Schiffmann; M Kruschewski; F Wacker; H J Buhr
Journal:  Surg Radiol Anat       Date:  2003-04-03       Impact factor: 1.246

2.  [A totally implantable permanent central venous access, long-term experience with subcutaneous infusion chambers].

Authors:  M Lorenz; C Hottenrott; R M Seufert; A Encke
Journal:  Langenbecks Arch Chir       Date:  1988

Review 3.  Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.

Authors:  J Greidanus; P H Willemse; D R Uges; E T Oremus; Z J De Langen; E G De Vries
Journal:  Pharm Weekbl Sci       Date:  1988-12-09

4.  Clinical evaluation of the CORDIS vascular access port systems: a multicenter study.

Authors:  A Hoekstra; V Bassot; S Bertoglio; J Y Bobin; P Delassus; R Egeli; D Khayat; J Y Ranchere; J Santini; P Segol
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

5.  Retention of drugs in venous access port chamber: a note of caution.

Authors:  M Ben-Arush; M Berant
Journal:  BMJ       Date:  1996-02-24

6.  Comparison between peripherally implanted ports and externally sited catheters for long-term venous access.

Authors:  A M Pullyblank; P D Carey; S Z Pearce; A G Tanner; P J Guillou; J R Monson
Journal:  Ann R Coll Surg Engl       Date:  1994-01       Impact factor: 1.891

Review 7.  Prevention and management of extravasation of cytotoxic drugs.

Authors:  G Bertelli
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

8.  A Wirelessly Controlled Scalable 3D-Printed Microsystem for Drug Delivery.

Authors:  Farzad Forouzandeh; Nuzhet N Ahamed; Xiaoxia Zhu; Parveen Bazard; Krittika Goyal; Joseph P Walton; Robert D Frisina; David A Borkholder
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-04

9.  Complications from port-a-cath system implantation in adults with malignant tumors: A 10-year single-center retrospective study.

Authors:  Yong Li; Jianxi Guo; Yanfang Zhang; Jian Kong
Journal:  J Interv Med       Date:  2021-12-09

10.  Implantable Port Devices, Complications and outcome in Pediatric Cancer, a Retrospective Study.

Authors:  H Esfahani; M Ghorbanpor; A Tanasan
Journal:  Iran J Ped Hematol Oncol       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.